NCT00426933View on ClinicalTrials.gov

Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Soft Tissue Infections
Interventions
DRUG

Daptomycin

DRUG

Vancomycin

Trial Locations (1)

83404

Idaho Falls Infectious Diseases, PLLC, Idaho Falls

All Listed Sponsors
lead

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00426933 - Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections | Biotech Hunter | Biotech Hunter